Objective to assess whether cardiovascular events are increased after cessation of dual antiplatelet therapy (DaPt) following acute coronary syndrome (acs) and to explore predictors for recurrent events after DaPt cessation during long-term follow-up. Methods We did a retrospective observational cohort study. We included consecutive people with acs who were discharged from scottish hospitals between January 2008 and December 2013 and who received DaPt after discharge followed by antiplatelet monotherapy. the rates of cardiovascular events were assessed during each 90-day period of DaPt treatment and 90-day period after stopping DaPt. cardiovascular events were defined as a composite of death, acs, transient ischaemic attack or stroke. cox regression was used to identify predictors of cardiovascular events following DaPt cessation. results 1340 patients were included (62% male, mean age 64.9 (13.0) years). cardiovascular events occurred in 15.7% (n=211) during the DaPt period (mean DaPt duration 175.1 (155.3) days) and in 16.7% (n=188) following DaPt cessation (mean of 2.7 years follow-up). independent predictors for a cardiovascular event following DaPt cessation were age (hr 1.07; 95% ci 1.05 to 1.08; p<0.001), DaPt duration (hr 0.997; 95% ci 0.995 to 0.998; p<0.001) and having revascularisation therapy during the index admission (hr 0.58; 95% ci 0.39 to 0.85; p=0.005). Conclusions the rate of cardiovascular events was not significantly increased in the early period postDaPt cessation compared with later periods in this acs population. increasing age, DaPt duration and lack of revascularisation therapy were associated with increased risk of cardiovascular events during long-term follow-up after DaPt cessation.
Original research article
Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome AbsTrACT Objective to assess whether cardiovascular events are increased after cessation of dual antiplatelet therapy (DaPt) following acute coronary syndrome (acs) and to explore predictors for recurrent events after DaPt cessation during long-term follow-up. Methods We did a retrospective observational cohort study. We included consecutive people with acs who were discharged from scottish hospitals between January 2008 and December 2013 and who received DaPt after discharge followed by antiplatelet monotherapy. the rates of cardiovascular events were assessed during each 90-day period of DaPt treatment and 90-day period after stopping DaPt. cardiovascular events were defined as a composite of death, acs, transient ischaemic attack or stroke. cox regression was used to identify predictors of cardiovascular events following DaPt cessation. results 1340 patients were included (62% male, mean age 64.9 (13.0) years). cardiovascular events occurred in 15.7% (n=211) during the DaPt period (mean DaPt duration 175.1 (155.3) days) and in 16 .7% (n=188) following DaPt cessation (mean of 2.7 years follow-up). independent predictors for a cardiovascular event following DaPt cessation were age (hr 1.07; 95% ci 1.05 to 1.08; p<0.001), DaPt duration (hr 0.997; 95% ci 0.995 to 0.998; p<0.001) and having revascularisation therapy during the index admission (hr 0.58; 95% ci 0.39 to 0.85; p=0.005). Conclusions the rate of cardiovascular events was not significantly increased in the early period postDaPt cessation compared with later periods in this acs population. increasing age, DaPt duration and lack of revascularisation therapy were associated with increased risk of cardiovascular events during long-term follow-up after DaPt cessation.
InTrOduCTIOn
Antiplatelet therapy is indicated after an acute coronary syndrome (ACS) because it lowers mortality and reduces the early risk of recurrence. Dual antiplatelet therapy (DAPT), typically using aspirin and an ADP receptor antagonist such as clopidogrel, ticagrelor or prasugrel, is superior to use of a single antiplatelet agent. Clopidogrel, when given together with aspirin and fibrinolytic therapy, has been shown to reduce the rate of death or reinfarction without major increased bleeding risk following ST elevation myocardial infarction (STEMI) when compared with aspirin alone. 1 2 Furthermore, patients with a non-STEMI (NSTEMI) ACS treated with both clopidogrel and aspirin had a lower rate of death from cardiovascular causes, non-fatal MI or stroke than patients treated with aspirin alone. 3 Typically, DAPT is given for a defined period of time after which patients continue with antiplatelet monotherapy. There are reports that the risk of cardiovascular events increases after DAPT is stopped, 4 5 perhaps due to a rebound in platelet activity. 6 Studies have shown that use of DAPT beyond 12 months significantly reduces risk of cardiovascular events. 7 8 Whether duration of DAPT is associated with risk of events after DAPT cessation is unclear. Most studies of risk after DAPT cessation also have short follow-up duration between 6 and 18 months, 4 9 included predominantly male patients 4 or patients with health insurance in specific healthcare plans. 5 10 A better understanding of the long-term outcomes after DAPT cessations and the predictors of events thereafter may help develop strategies to mitigate this risk.
The National Health Service (NHS) Scotland has set up regional data Safe Havens which aim to facilitate rapid access to high-quality health data for research purposes. 11 We used data contained in NHS Greater Glasgow and Clyde (NHS GGC) Safe Haven to assess the incidence and predictors of cardiovascular events after discontinuation of DAPT in patients who have suffered ACS. We hypothesised that discontinuation of DAPT would increase the risk of cardiovascular events in the first 90-day interval after stopping DAPT.
MeThOds study design
We undertook a retrospective observational cohort study using healthcare records obtained from NHS GGC. NHS GGC is the largest health board in Scotland, serving a catchment area including the City of Glasgow, Inverclyde, Renfrewshire, East Renfrewshire, East Dunbartonshire and West Dunbartonshire. Approval was obtained from the NHS GGC Safe Haven advisory committee, which has approval from the West of Scotland Research Ethics Committee (GSH/13/CA/005). The study adhered to strict information governance and security protocols. All data are held within the NHS GGC Safe Haven with restricted access. data source NHS GGC and the Robertson Centre for Biostatistics provide access to anonymised local healthcare Coronary artery disease data in the West of Scotland subject to the approvals described. We incorporated data from the Scottish Morbidity Record, the General Register Office for Scotland death registration records, the Prescribing Information System, the Scottish Care Information-Diabetes Collaboration (SCI-DC) and the General Practice database. The Scottish Morbidity Record database was used to search all admission for ACS that occurred in the West of Scotland from January 2008 through December 2013.
study setting and study population
Patients were included in the study if they experienced an ACS, continued on DAPT following discharge (defined as cashing a prescription for DAPT within 60 days of hospital discharge) and subsequently stopped DAPT and then continued with single antiplatelet therapy. An ACS event was defined as emergency hospital admission with a main discharge diagnosis of ACS (International Classification of Diseases-Tenth revisions (ICD-10) codes I20, I21 or I22).
Baseline demographic data were obtained from the Scottish Morbidity Record dataset. Medical history data were obtained from the General Practice and the SCI-DC databases. These comorbidities were defined as a condition reported from general practitioners before the ACS event. A coronary revascularisation procedure was defined as a procedure listed in operation field from Scottish Morbidity Record dataset during the index admission. Revascularisation procedures include coronary artery bypass graft (English Office of Population Censuses and Surveys (OPCS-4) codes K40-46) and percutaneous coronary intervention (OPCS-4 codes K49-50 and K75).
dAPT use
The usage of DAPT was identified and verified through the Prescribing Information System database. DAPT use included a combination of aspirin-clopidogrel, aspirin-dipyridamole, aspirin-ticagrelor and aspirin-prasugrel. The number of pills dispensed for each prescription was used to calculate the duration of DAPT use. In the primary analysis, the last day of DAPT use was based on the date of last DAPT prescription refill plus the number of days supplied for that refill. Discontinuation of DAPT was defined when there was no refill prescription or dispense date of DAPT more than 14 days after this date.
study endpoints
The primary endpoint of the study was a cardiovascular event, which consists of composite of all-cause mortality, ACS (MI or unstable angina), transient ischaemic attack (TIA) or stroke after cessation of DAPT. Information on death was obtained through General Register Office for Scotland database. The ICD-10 codes were used to identify hospitalisations for ACS (I20-I25), TIA (G458-G459) and stroke (I63-I64). The safety endpoint of the study was a major bleeding event following the first admission of ACS. Major bleedings were based on ICD-10 (I60-I62, H11.3, H31.3, H35.6, H43.1 and R58)
statistical methods
Descriptive statistics are given for the whole population and separately for patients treated with medical or revascularisation therapy for the index ACS. Categorical variables were summarised using frequencies and proportions and continuous variables as mean (SD) or median (IQR). Patients were censored at the end of the follow-up period.
The life table method was used to calculate unadjusted incidence rates per 1000 patient-days of the primary endpoint for each 90-day interval during DAPT and after DAPT cessation. Incidence rate ratios (IRR) with 95% CI were calculated to compare incidence rates in patients treated with medical and revascularisation therapy during the same intervals.
Poisson regression (or negative binomial if overdispersion was present) model was used to assess incidence of the primary endpoint after stopping DAPT. IRRs were calculated with adjustment for age, medical or revascularisation therapy and duration of DAPT. In these models, the risk of cardiovascular events in the first 90-day interval after stopping DAPT was compared with 91-180-day interval after stopping and with 91-360-day interval consistent with prior studies. 4 5 Cox regression analysis was used to model the predictors of cardiovascular events after stopping DAPT. The models were adjusted for age, medical or revascularisation therapy and duration of DAPT. Adjustment was not made for other risk factors such as hypertension, diabetes, hyperlipidaemia, chronic renal failure and ischaemic heart disease because of missing data. The proportional hazards assumption was tested by using log-minus-log plots. We found no evidence of violation of this assumption. The adjusted HRs and 95% CI for cardiovascular event were estimated and adjusted to age, medical or revascularisation therapy and duration of DAPT. The Harrell's C statistic result for the overall model prediction accuracy was reported. The Fine-Gray model for the competing risk of death was used as a sensitivity analysis, 12 and the subdistribution HR (SHR) and 95% CI of SHR were estimated.
Statistical analyses were performed using IBM SPSS Statistics V.21.0, 13 and competing risk analyses were performed using STATA V.15.0 (University of Glasgow). A value of p<0.05 was considered statistically significant.
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resulTs
Of the 7232 patients admitted with an ACS during the study period, 2899 (40%) patients received only single antiplatelet therapy, and 1531 (21%) had no documented antiplatelet information leaving 2802 (38.7%) patients who were dispensed with DAPT. Of these 2802 patients, 1872 patients were confirmed to refill a prescription for DAPT within 60 days of hospital discharge. Of these, 1340 (71.6%) had DAPT then continued with a single antiplatelet in the longer term and were (figure 1) included in the study. Baseline characteristics are shown in table 1. Mean follow-up after DAPT cessation was 1009 days, with a median of 1067 days (online supplementary figure) . Following DAPT cessation, antiplatelet monotherapy with aspirin was commonly prescribed (79.1%), followed by clopidogrel (19.8%), then dipyridamole (0.6%) and ticagrelor (0.4%).
study endpoints
Cardiovascular events occurred in 211 (15.7%) while taking DAPT, leaving 1129 (84.3%) event-free at DAPT cessation. After DAPT cessation, 188 cardiovascular events occurred (16.7%) (table 2). Major bleeding occurred in 6 (0.45%) and 5 (0.44%) while on DAPT and after DAPT cessation, respectively.
Cardiovascular events
The incidence rate was higher in the first 90 days of DAPT treatment compared with the following 90 days of DAPT treatment (IRR 5.73; 95% CI 3.48 to 10.06; p<0.001) (table 3). After cessation of DAPT, the incidence rate was figure 1 Flow diagram describing the selection of data for the analysis reported. ACS, acute coronary syndrome; AP, antiplatelet; DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy.
not different in the first 90 days compared with the next 90 days (IRR 0.65; 95% CI 0.31 to 1.31; p=0.190). Medically treated had a higher incidence of cardiovascular events during DAPT in the first 90 days (IRR 2.57; 95% CI 1.71 to 3.99; p<0.001) (figure 2A) compared with patients treated with revascularisation therapy. After cessation of DAPT, there was no difference in the incidence rate of cardiovascular event between patients treated with medical and revascularisation therapy in the first 90-day interval (IRR 3.30; 95% CI 0.75 to 30.12; p=0.096) (figure 2B).
Adjusted Irrs following dAPT cessation
After adjusting for age, medical or revascularisation therapy and total duration of DAPT treatment, there was no increased risk of cardiovascular events in the first 90 days after DAPT cessation (adjusted IRR 0.70; 95% CI 0.32 to 1.55; p=0.375) compared with 91-180 days (table 4) .
Predictors of cardiovascular events following dAPT cessation
The univariable and multivariable analyses of possible predictors of risk of cardiovascular events after stopping DAPT are presented in table 5. Multivariable analysis of the Cox model indicated that increased age (HR 1.07; 95% CI 1.05 to 1.08; p<0.001) was significantly associated with an increased risk of cardiovascular event, whereas patients treated with revascularisation (HR 0.58; 95% CI 0.39 to 0.85; p=0.005) and longer duration of DAPT (HR 0.997; 95% CI 0.995 to 0.998; p<0.001) had lower risk (Harrell's C statistic=0.77). Results were broadly consistent with Fine-Gray model.
dIsCussIOn
We assessed the rate of cardiovascular events following DAPT cessation and explored predictors of events during long-term follow-up after DAPT cessation. The incidence was not higher in the first 90 days post-DAPT cessation compared with later periods, suggesting no rebound increase in risk in this population. All values are reported as no (%) unless otherwise noted. Revascularisation includes CABG and PCI. AP, antiplatelet; CABG, coronary artery bypass graft; CRF, chronic renal failure; DAPT, dual antiplatelet therapy; IHD, ischaemic heart disease; PCI, percutaneous coronary intervention. Cardiovascular events did occur in the long-term follow-up period after DAPT cessation, and we found that increasing age, lack of revascularisation treatment for the ACS and duration of DAPT treatment were independent predictors of cardiovascular event following DAPT cessation. The incidence of cardiovascular events following DAPT cessation in the literature varies between studies (4%-17%). The incidence in the present study (16.7%) is at the higher end of this range, and this could be due to longer follow-up period, that is, 2.7-year follow-up, which allowed us to capture more events. We did not see an increase in risk following DAPT cessation. This is in contrast to many other studies. 4 5 9 10 There are several differences between our and other studies to note. These differences may be due to differences in definitions used of cardiovascular event between studies 14 and differences in the duration of DAPT after ACS (in the present study was 177 (155) days, which was shorter than previous studies). 9 10 The shorter duration of DAPT in Table 3 The risk of cardiovascular events* following ACS and up to 2 years after stopped DAPT this study was 5.8 months, and this is probably due to the recommendation made by the Cardiac Prescribing Group West of Scotland. This recommends 3 and 6 months of DAPT following a STEMI or NSTEMI for use of bare metal stent and drug-eluting stents, respectively. More patients in our study were treated with medical therapy alone for their ACS, 67% compared with 50% and 25% in the studies by Ho et al 4 and Stephenson et al, respectively. 10 We explored predictors of long-term events after DAPT cessation. We found that increasing age, DAPT duration and lack of revascularisation therapy for the ACS were associated with increased risk of cardiovascular events after DAPT cessation. Previous studies have demonstrated that usage of clopidogrel for more than 6 months was associated with lower rates of death, MI and/or stent thrombosis. 15 16 These data suggest that patients with ACS may benefit when the duration of DAPT is more than 6 months. In contrast, a network meta-analysis by D'Ascenzo et al 17 found shorter DAPT duration (<12 months) is associated with lower rates of ischaemic events in everolimus/zotarolimus-eluting stents than bioresorbable stents. These data suggest that type of stent and DAPT duration may affect the cardiovascular events at follow-up.
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strengths
Our study had full information on antiplatelet use through the Prescribing Information System database. Thus, we were able to confirm that all patients included in this study were taking aspirin plus either clopidogrel or prasugrel or ticagrelor and which antiplatelet they took following DAPT cessation. This is in contrast to some previous studies where this information was not available. 5 10 18 We included ACS population in the West of Scotland. Ours is a study of all individuals in a community with an ACS identified through resources of the NHS GGC Safe Haven, regardless of sex and healthcare insurance. In previous studies, they were only able to include predominantly male patients 4 or patients treated within a particular healthcare plan. 5 10 
study limitations
Many patients with a diagnosis of ACS were not included in our analysis. This is because many received only single antiplatelet therapy, many did not continue receiving prescriptions for DAPT and many did not stop DAPT and then continue with antiplatelet monotherapy. There are several reasons for this. First, patients may be coded as an ACS in hospital records but have not met the criteria for DAPT use. Patients who did not receive a further prescription for DAPT within 60 days of discharge may have stopped DAPT due to side effects or bleeding complications, meaning our estimates of bleeding may be falsely low. Patients admitted near the end of the study window may not have reached the end of their DAPT treatment course.
This was an observational analysis, and the combinations of DAPT were not randomly assigned. We excluded all patients who did not have their antiplatelet therapy recorded in the Prescribing Information System database. Owing to exclusion of these patients from the analysis, it could raise the likelihood that the observed effect estimate is biased. We included 33 patients with ACS who were prescribed with aspirin and dipyridamole; however, we were unable to determine the rationale for this treatment decision. We assume that it is due to ischaemic stroke.
We lack specific measures of indications for stopping DAPT such as bleeding, switching to other antiplatelet, stopping for surgery or lack of adherence. We assume that in most cases, the cessation of DAPT was planned. Although we could not directly measure medication adherence, we did use pharmacy dispensing data, which is strongly correlated with a broad range of patient outcomes. 19 Use of prescriptions filled has been shown to reflect medication use by the patient with a high degree of accuracy. 20 We also lack Coronary artery disease figure 2 Incidence rate (A) during DAPT and (B) after DAPT cessation for patients treated with medical and revascularisation therapy. *p<0.01, †p<0.05, compared with patients treated with revascularisation therapy from the same interval. ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy. information on the type of coronary lesion and the type of stents used in revascularisation group. The use of overthe-counter medicines was not available 21 in this study that could be potential confounding factors. Patients in Scotland receive free prescriptions, which should reduce the possibility of over-the-counter medicine use. The present study included patients admitted with ACS in the West of Scotland; thus, generalisability to other populations and practice setting is unknown. The different incidence rates between patients treated with medical and revascularisation therapy in the early period did not show a significant difference because of the low number of events in each group and the wide CIs.
COnClusIOns
In ACS population, the incidence of cardiovascular events was not higher early post-DAPT cessation than in later periods. Cardiovascular events post-DAPT cessation did occur and were associated with increasing age, DAPT duration and lack of revascularisation therapy.
Key messages
What is already known on this subject? ► Discontinuation of dual antiplatelet therapy (DAPT) is associated with an increased risk of cardiovascular disease in previous studies. The association between the duration of DAPT and DAPT cessation is unknown.
What might this study add? ► We found that increasing age, DAPT duration and lack of revascularisation therapy for the acute coronary syndrome (ACS) were associated with increased risk of cardiovascular events during long-term follow-up after DAPT cessation.
how might this impact on clinical practice? ► Our findings indicate that longer duration of DAPT and use of revascularisation therapy may be related to a reduced risk of cardiovascular event after ACS and DAPT cessation.
